Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel

Table 4

Number of patients experiencing the most frequent treatment-related adverse events.

	Grade 1	Grade 2	Grade 3
Hematological
Neutropenia	19 (44.1%)	14 (32.5%)	8 (18.6%)
Anemia	20 (46.5%)	15 (34.8%)	6 (13.9%)
Thrombocytopenia	18 (41.8%)	12 (27.9%)	4 (9.3%)
Nonhematological
Nausea/vomiting	12 (27.9%)	8 (18.6%)	0
Diarrhea	9 (20.9%)	6 (13.9%)	0
Constipation	13 (30.2)	11(25.5%)	0
Nail changes	22 (51.1% )	17 (39.5%)	2 (4.6%)
Dry eye/tearing	26 (60.4%)	15 (34.8%)	0
Myalgia/arthralgia	22 (51.1%)	14 (32.5%)	0
Fatigue	21 (48.8%)	18 (41.8%)	2 (4.6%)
Sensory neuropathy	16 (37.2%)	7 (16.2%)	0
Peripheral edema	22 (51.1%)	8 (18.6%)	0
Epistaxis	23 (53.4%)	7 (16.2%)	1 (2.3%)
Dyspnea	12 (27.9%)	5 (11.6%)	0